LU88746I2 - Valaciclovir facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le sel d'addition de l'acide chlorhydrique - Google Patents

Valaciclovir facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le sel d'addition de l'acide chlorhydrique

Info

Publication number: LU88746I2
Authority: LU; Luxembourg
Prior art keywords: valaciclovir; optionally; pharmaceutically acceptable; hydrochloric acid; acceptable salt
Prior art date: 1987-08-15

Application number

LU88746C

Other languages

English (en)

Original Assignee

Wellcome Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-08-15

Filing date

1988-08-12

Publication date

1996-10-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26292613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU88746(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1987-08-15 Priority claimed from GB878719367A external-priority patent/GB8719367D0/en

1987-11-05 Priority claimed from GB878725939A external-priority patent/GB8725939D0/en

1988-08-12 Application filed by Wellcome Found filed Critical Wellcome Found

1996-10-04 Publication of LU88746I2 publication Critical patent/LU88746I2/fr

Links

VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title 2
150000003839 salts Chemical class 0.000 title 2
HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 title 1
229940093257 valacyclovir Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Communicable Diseases (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Oncology (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

LU88746C 1987-08-15 1988-08-12 Valaciclovir facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le sel d'addition de l'acide chlorhydrique LU88746I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB878719367A GB8719367D0 (en)	1987-08-15	1987-08-15	Therapeutic compounds
GB878725939A GB8725939D0 (en)	1987-11-05	1987-11-05	Therapeutic compounds

Publications (1)

Publication Number	Publication Date
LU88746I2 true LU88746I2 (fr)	1996-10-04

Family

ID=26292613

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU88746C LU88746I2 (fr)	1987-08-15	1988-08-12	Valaciclovir facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le sel d'addition de l'acide chlorhydrique

Country Status (30)

Country	Link
EP (2)	EP0596542B1 (fr)
JP (2)	JPH0662623B2 (fr)
KR (2)	KR960002849B1 (fr)
CN (1)	CN1033701C (fr)
AP (2)	AP160A (fr)
AT (1)	ATE138660T1 (fr)
AU (1)	AU612393C (fr)
CS (1)	CS276903B6 (fr)
CY (1)	CY1833A (fr)
DE (1)	DE3855333T2 (fr)
DK (2)	DK170045B1 (fr)
ES (1)	ES2087639T3 (fr)
FI (1)	FI89713C (fr)
GR (1)	GR3020372T3 (fr)
HU (1)	HU201071B (fr)
IE (1)	IE65551B1 (fr)
IL (1)	IL87434A (fr)
LU (1)	LU88746I2 (fr)
LV (1)	LV5264A3 (fr)
MC (1)	MC1968A1 (fr)
MX (1)	MX9203418A (fr)
MY (1)	MY103760A (fr)
NL (1)	NL960001I2 (fr)
NO (2)	NO167805C (fr)
NZ (1)	NZ225809A (fr)
PL (1)	PL158285B1 (fr)
PT (1)	PT88261B (fr)
SA (1)	SA95160244B1 (fr)
SG (1)	SG26346G (fr)
SU (1)	SU1634138A3 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AP160A (en) *	1987-08-15	1991-11-18	The Wellcome Foundation Ltd	Therapeutic acyclic nucleosides.
GB8816760D0 (en) *	1988-07-14	1988-08-17	Wellcome Found	Therapeutic compounds
GB8829571D0 (en) *	1988-12-19	1989-02-08	Wellcome Found	Antiviral compounds
AU618436B2 (en) *	1988-12-19	1991-12-19	Wellcome Foundation Limited, The	Antiviral cytosine and guanine derivatives
DE4008858A1 (de) *	1990-03-20	1991-09-26	Hoechst Ag	Substituierte purine, verfahren zu ihrer hertellung sowie ihre verwendung als antivirale mittel
NZ266527A (en) *	1993-06-08	1999-10-28	Cancer Res Campaign Tech	Alkylguanine derivatives and pharmaceutical compositions
US5831075A (en) *	1993-06-10	1998-11-03	Rolabo Sl	Amino acid ester of nucleoside analogues
GB9317146D0 (en) *	1993-08-18	1993-10-06	Wellcome Found	Therapeutic combinations
GB9320316D0 (en) *	1993-10-01	1993-11-17	Smithkline Beecham Plc	Pharmaceuticals
TW282470B (fr) *	1993-11-18	1996-08-01	Ajinomoto Kk
EP0665229B1 (fr) *	1994-02-01	1999-11-17	Ajinomoto Co., Inc.	Procédé pour la production de dérivés d'une base d'acide nucléique
US5543414A (en) *	1994-07-28	1996-08-06	Syntex (Usa) Inc.	Achiral amino acid acyl esters of ganciclovir and its derivatives
US5840891A (en) *	1994-07-28	1998-11-24	Syntex (U.S.A.) Inc.	2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
PE32296A1 (es) *	1994-07-28	1996-08-07	Hoffmann La Roche	Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables
GB9501178D0 (en) *	1995-01-20	1995-03-08	Wellcome Found	Guanine derivative
GB9501127D0 (en) *	1995-01-20	1995-03-08	Wellcome Found	Tablet
GB9501142D0 (en) *	1995-01-20	1995-03-08	Wellcome Found	Compounds for use in medicine
DE19536164A1 (de) *	1995-09-28	1997-04-03	Boehringer Ingelheim Kg	Verbessertes Verfahren zur Herstellung von 9-[(2-Hyroxyethoxy)methyl]guanin (Acyclovir)
ZA97400B (en) *	1996-01-19	1997-11-13	Glaxo Group Ltd	Valaciclovir.
US5756736A (en) *	1996-01-26	1998-05-26	Syntex (U.S.A.) Inc.	Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
WO1997027198A1 (fr) *	1996-01-26	1997-07-31	F.Hoffmann-La Roche Ag	Procede pour la preparation de derives de la purine
US5840890A (en) *	1996-01-26	1998-11-24	Syntex (U.S.A.) Inc.	Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US5700936A (en) *	1996-01-26	1997-12-23	Syntex (U.S.A.) Inc.	Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol valinate
US6040446A (en)	1996-01-26	2000-03-21	Syntex (U.S.A.) Inc.	Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
US6703394B2 (en)	1996-02-16	2004-03-09	Medivir Ab	Acyclic nucleoside derivatives
US5869493A (en) *	1996-02-16	1999-02-09	Medivir Ab	Acyclic nucleoside derivatives
IT1283447B1 (it) *	1996-07-18	1998-04-21	Ind Chimica Srl	Processo di preparazione del valaciclovir e relativi intermedi
CN1250449A (zh) *	1997-01-17	2000-04-12	味之素株式会社	新型z－伐昔洛韦结晶
CA2332961A1 (fr) *	1998-05-21	1999-11-25	Michael Zasloff	Procede de stimulation de la production de defensine par exposition a de l'isoleucine
EP1436295A4 (fr) *	2001-09-07	2007-07-11	Teva Pharma	Formes cristallines de chlorhydrate de valacyclovir
EP1517678A2 (fr)	2002-06-24	2005-03-30	Ranbaxy Laboratories Limited	Procede de preparation de formulations solides de comprimes de chlorhydrate de valacyclovir
US20050043329A1 (en) *	2002-09-06	2005-02-24	Shlomit Wizel	Crystalline forms of valacyclovir hydrochloride
CN1309732C (zh) *	2002-10-28	2007-04-11	南京长澳医药科技有限公司	6－烷氧基－2’，3’－双脱氧鸟嘌呤核苷的制备方法
KR100871621B1 (ko) *	2003-06-02	2008-12-02	테바 파마슈티컬 인더스트리즈 리미티드	발라시클로비르 히드로클로라이드의 신규한 결정질 형태
CN1331471C (zh) *	2003-09-22	2007-08-15	陈云芳	盐酸万乃洛韦软胶囊组合物
MXPA06008197A (es) *	2004-01-21	2007-04-02	Teva Pharma	Proceso para la preparacion de clorhidrato de valaciclovir.
GB2413017A (en) *	2004-04-06	2005-10-12	Ford Global Tech Llc	An electrical connector for a vehicle
WO2006035452A1 (fr) *	2004-09-27	2006-04-06	Matrix Laboratories Ltd	Nouveau pseudomorphe d'hydrochlorure de valaciclovir
US7846937B2 (en)	2005-05-25	2010-12-07	Eli Lilly And Company	Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (fr)	2005-07-21	2007-01-24	SOLMAG S.p.A.	Des polymorphes de valacyclovir et procédé pour leur fabrication
CN101456859B (zh) *	2009-01-06	2011-07-20	华南理工大学	抗病毒药物缬昔洛韦的制备方法
WO2011158252A1 (fr)	2010-06-15	2011-12-22	Matrix Laboratories Ltd	Méthode de préparation de la forme polymorphe ii du chlorhydrate de valacyclovir
CN102850354B (zh) *	2012-10-10	2014-07-23	山东金城医药化工股份有限公司	高纯度cbz-万乃洛韦的制备方法
CN106632335A (zh) *	2016-12-27	2017-05-10	河南康达制药有限公司	一种盐酸伐昔洛韦的制备方法
RU2750867C1 (ru) *	2020-05-18	2021-07-05	Александр Сергеевич Самойлов	Производные гуанина

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL8202626A (nl) *	1982-06-29	1984-01-16	Stichting Rega V Z W	Derivaten van 9-(2-hydroxyethoxymethyl)guanine.
DE3627024A1 (de) *	1985-09-24	1987-04-02	Hoechst Ag	In 6- und 9-stellung substituierte 2-aminopurine, ihre verwendung, diese purine enthaltende arzneimittel und verfahren zur herstellung der purine
DE3534774A1 (de) *	1985-09-30	1987-04-02	Robugen Gmbh	Nucleosid-analoge verbindungen mit antiviraler aktivitaet, verfahren zu deren herstellung sowie arzneimittel mit antiviraler wirkung
AP160A (en) *	1987-08-15	1991-11-18	The Wellcome Foundation Ltd	Therapeutic acyclic nucleosides.

1988
- 1988-08-10 AP APAP/P/1991/000238A patent/AP160A/en active
- 1988-08-10 AP APAP/P/1988/000099A patent/AP55A/en active
- 1988-08-11 MC MC881999A patent/MC1968A1/fr unknown
- 1988-08-12 NZ NZ225809A patent/NZ225809A/en unknown
- 1988-08-12 AU AU20978/88A patent/AU612393C/en not_active Expired
- 1988-08-12 ES ES93120604T patent/ES2087639T3/es not_active Expired - Lifetime
- 1988-08-12 SU SU884356404A patent/SU1634138A3/ru active
- 1988-08-12 HU HU884332A patent/HU201071B/hu unknown
- 1988-08-12 KR KR1019880010298A patent/KR960002849B1/ko not_active Expired - Lifetime
- 1988-08-12 FI FI883757A patent/FI89713C/fi not_active IP Right Cessation
- 1988-08-12 NO NO883612A patent/NO167805C/no not_active IP Right Cessation
- 1988-08-12 AT AT93120604T patent/ATE138660T1/de not_active IP Right Cessation
- 1988-08-12 IE IE246388A patent/IE65551B1/en not_active IP Right Cessation
- 1988-08-12 CS CS885594A patent/CS276903B6/cs not_active IP Right Cessation
- 1988-08-12 IL IL87434A patent/IL87434A/xx not_active IP Right Cessation
- 1988-08-12 DE DE3855333T patent/DE3855333T2/de not_active Expired - Lifetime
- 1988-08-12 MY MYPI88000934A patent/MY103760A/en unknown
- 1988-08-12 JP JP63200320A patent/JPH0662623B2/ja not_active Expired - Lifetime
- 1988-08-12 EP EP93120604A patent/EP0596542B1/fr not_active Expired - Lifetime
- 1988-08-12 PT PT88261A patent/PT88261B/pt not_active IP Right Cessation
- 1988-08-12 DK DK451388A patent/DK170045B1/da not_active IP Right Cessation
- 1988-08-12 PL PL1988274215A patent/PL158285B1/pl unknown
- 1988-08-12 CN CN88106535A patent/CN1033701C/zh not_active Expired - Lifetime
- 1988-08-12 LU LU88746C patent/LU88746I2/fr unknown
- 1988-08-12 EP EP88307512A patent/EP0308065B1/fr not_active Expired - Lifetime
1990
- 1990-08-28 JP JP2226434A patent/JPH07113025B2/ja not_active Expired - Lifetime
1992
- 1992-06-25 MX MX9203418A patent/MX9203418A/es unknown
- 1992-12-18 LV LV920335A patent/LV5264A3/xx unknown
1994
- 1994-07-08 DK DK082694A patent/DK170803B1/da not_active IP Right Cessation
1995
- 1995-02-24 SG SG1995903373A patent/SG26346G/en unknown
- 1995-09-20 SA SA95160244A patent/SA95160244B1/ar unknown
- 1995-12-01 CY CY183395A patent/CY1833A/xx unknown
1996
- 1996-01-17 KR KR1019960000775A patent/KR960004940B1/ko not_active Expired - Lifetime
- 1996-01-18 NL NL960001C patent/NL960001I2/nl unknown
- 1996-06-27 GR GR960401743T patent/GR3020372T3/el unknown
- 1996-12-17 NO NO1996015C patent/NO1996015I1/no unknown

Also Published As

Publication number	Publication date
AP8800099A0 (en)	1988-08-01
EP0596542A1 (fr)	1994-05-11
DE3855333T2 (de)	1996-12-05
AU612393C (en)	2006-08-17
DK170803B1 (da)	1996-01-22
IL87434A0 (en)	1989-01-31
DK451388A (da)	1989-02-16
IE882463L (en)	1989-02-15
IL87434A (en)	1993-06-10
CS8805594A2 (en)	1990-06-13
KR960002849B1 (ko)	1996-02-27
NZ225809A (en)	1991-07-26
LV5264A3 (lv)	1993-10-10
HU201071B (en)	1990-09-28
FI883757A0 (fi)	1988-08-12
CN1033701C (zh)	1997-01-01
NO883612L (no)	1989-02-16
AP55A (en)	1989-09-26
GR3020372T3 (en)	1996-09-30
MX9203418A (es)	1992-07-01
KR960004940B1 (ko)	1996-04-18
EP0308065B1 (fr)	1995-01-04
NO167805C (no)	1991-12-11
PT88261B (pt)	1995-03-01
NO883612D0 (no)	1988-08-12
JPH07113025B2 (ja)	1995-12-06
MY103760A (en)	1993-09-30
DK82694A (da)	1994-07-08
EP0596542B1 (fr)	1996-05-29
MC1968A1 (fr)	1989-09-29
SA95160244B1 (ar)	2006-10-02
AP160A (en)	1991-11-18
AU2097888A (en)	1989-02-16
AU612393B2 (en)	1991-07-11
FI89713C (fi)	1993-11-10
ATE138660T1 (de)	1996-06-15
JPS6468373A (en)	1989-03-14
PL158285B1 (en)	1992-08-31
JPH0662623B2 (ja)	1994-08-17
DK170045B1 (da)	1995-05-08
HUT47935A (en)	1989-04-28
IE65551B1 (en)	1995-11-01
EP0308065A3 (en)	1989-09-27
DE3855333D1 (de)	1996-07-04
PL274215A1 (en)	1990-02-19
CS276903B6 (en)	1992-09-16
NL960001I2 (nl)	1996-11-01
KR890003761A (ko)	1989-04-17
JPH03115284A (ja)	1991-05-16
SU1634138A3 (ru)	1991-03-07
CY1833A (en)	1995-12-01
EP0308065A2 (fr)	1989-03-22
CN1032538A (zh)	1989-04-26
NO167805B (no)	1991-09-02
PT88261A (pt)	1989-06-30
ES2087639T3 (es)	1996-07-16
FI883757L (fi)	1989-02-16
DK451388D0 (da)	1988-08-12
NL960001I1 (nl)	1996-03-01
SG26346G (en)	1995-09-01
FI89713B (fi)	1993-07-30
NO1996015I1 (no)	1996-12-17

Publication	Publication Date	Title
LU88746I2 (fr)	1996-10-04	Valaciclovir facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le sel d'addition de l'acide chlorhydrique
LU90426I2 (fr)	1999-10-06	Abacavir facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un d-rive y compris le sulfate d'abacavir
LU88809I2 (fr)	1997-01-03	Lamivudine facultativement sous la forme d'un sel pharmaceutiquement acceptable
LU90593I2 (fr)	2000-08-07	Quetiapine facutativement sous forme d'un sel pharmaceutiquement acceptabe
LU91306I2 (fr)	2007-03-19	Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN)
LU90468I2 (fr)	2000-01-03	Zanamivir facultativement sous la forme d'un sel ou d'un derive pharmaceutiquement acceptable
LU91290I2 (fr)	2007-01-22	Céfovécine, optionnellement sous la forme d'un sel, dont le sel de sodium (CONVENIAr)
LU91372I2 (fr)	2007-12-24	Retapamulin optionnellement sous forme d'un sel pharmaceutiquement acceptable (altargo)
LU88842I2 (fr)	1997-01-27	Nebivolol optionnellement sous forme d'un sel ou d'un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol
LU90097I2 (fr)	1997-07-16	Ropinirole facultativement sous forme de sels pharmaceutiquement acceptables et de préférence le sel hydrochlorique
LU91599I2 (fr)	2009-10-19	Lasofoxifene, optionnellement sous forme d'un sel d'addition acide, d'un N-oxyde, d'unester ou d'un sel d'ammonium quaternaire, non toxiques et pharmacologiquement acceptables, y compris le sel tartrate (FABLYN - lasofoxifene)
LU92407I2 (fr)	2014-05-19	Afatinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable, y compris le sel dimaléate
LU91442I2 (fr)	2008-07-21	"Varénicline, optionnellement sous forme d'un sel pharmaceutiquement acceptable, y compris le sel tartrate"
LU91181I2 (fr)	2005-09-06	Ziconotide, optionnellement sous forme d'un sel avec un acide pharmaceutiquement acceptable, y compris acetate de ziconotide (prialt).
FI895417A0 (fi)	1989-11-14	Menetelmä uusien terapeuttisesti käyttökelpoisten 2'-halometylideeninukleosidien valmistamiseksi
GB2206334B (en)	1991-10-23	Improvements in or relating to casket liners
FR2567540B1 (fr)	1988-10-14	Procede de preparation d'un interferon leucocytaire humain alpha-2
LV5765A4 (lv)	1996-12-20	(S)-(-)-1-propil-2',6'-pipekoloksilidida hidrohlorida monohidrats ta iegusanas metode un to satuross farmaceitisks preparats
FR2609391B1 (fr)	1991-02-15	Preparations pharmaceutiques sous forme de suppositoires bioadhesifs
FI900145L (fi)	1990-01-11	Menetelmä farmaseuttisesti käyttökelpoisten 1,1-diokso-kefem-4-karbotiolihappojohdannaisten valmistamiseksi
EP0353474A3 (fr)	1991-03-27	Dérivé de glycérol et son utilisation pharmaceutique
FR2626884B1 (fr)	1991-11-08	Procede de preparation de n-phosphonomethyl-imino-diacetique et de chlorure d'acide en resultant
GB2207642B (en)	1991-09-04	Improvements in or relating to the buoyant support of flexible structures
FR2650272B1 (fr)	1992-08-28	Procede de dedoublement d'intermediaires interessants dans la preparation de diltiazem
BE893562A (fr)	1982-10-18	Compositions pharmaceutiques antibronchospastiques solubles dans l'eau consistant en des sels de theophylline avec des aminoacides basiques